Tarsus Pharmaceuticals: An Undervalued Growth Story?

Tarsus Pharmaceuticals (Nasdaq:TARS) has garnered attention recently due to its mixed share performance. While the stock has experienced a decline over the past three months, it has shown gains in the last month, prompting renewed interest in its valuation and business outlook. Current analysis suggests the company may be undervalued, but potential risks and market conditions warrant careful consideration.

Recent Performance and Valuation

As of March 6, 2026, Tarsus Pharmaceuticals’ share price is $73.26, reflecting a 13.37% increase over the past month. Still, year-to-date performance has been weaker. Despite this recent volatility, the company’s one-year and three-year total shareholder returns remain strong, potentially indicating that changing risk and growth expectations are being factored into the market price. Stockanalysis.com

Analysts following Tarsus Pharmaceuticals estimate a fair value of $87.50 per share, suggesting the stock is currently trading below its intrinsic value. This gap is driven by assumptions regarding future growth and margin expansion. The company’s market capitalization is $3.12 billion. Stockanalysis.com

Growth Drivers and Pipeline Expansion

A key factor supporting the positive outlook for Tarsus Pharmaceuticals is its pipeline expansion, particularly the development of TP-04, a sterile aqueous gel formulation of lotilaner for ocular rosacea. This positions the company for multi-product leverage in underserved markets, potentially supporting diversified, long-term earnings growth and reducing reliance on its current primary product, XDEMVY. Stockanalysis.com

XDEMVY is a lotilaner ophthalmic solution used for the treatment of demodex blepharitis, caused by Demodex mite infestation. Tarsus Pharmaceuticals sells its products to specialty pharmacies, distributors, clinics, hospitals and federal healthcare programs. Stockanalysis.com

Financial Performance

In 2025, Tarsus Pharmaceuticals reported revenue of $451.36 million, a significant increase of 146.7% compared to the $182.95 million reported in 2024. However, the company experienced a net loss of $66.42 million in 2025, an improvement from the $86.78 million loss in 2024. Stockanalysis.com

Analyst Ratings and Price Targets

Currently, nine analysts rate Tarsus Pharmaceuticals stock as a “Strong Buy,” with an average 12-month price target of $80.56, representing a potential 9.97% increase from the current price. Stockanalysis.com

Potential Risks and Considerations

Despite the optimistic outlook, potential risks exist. Slow adoption of XDEMVY or continued high selling and advertising costs could negatively impact margins and cash generation. The company’s reliance on a single product also exposes it to revenue risk amid regulatory pressures and evolving payer dynamics. Simply Wall St

The Price-to-Sales (P/S) ratio for Tarsus Pharmaceuticals is 6.9x, which is higher than the industry average of 3.9x for US Pharmaceuticals companies, but lower than its peers at 13.7x. This suggests both upside and downside risk. Simply Wall St

Key Takeaways

• Tarsus Pharmaceuticals is currently trading below its estimated fair value of $87.50.
• The company’s pipeline expansion, particularly TP-04, is a key growth driver.
• Revenue increased significantly in 2025, but the company remains unprofitable.
• Analysts maintain a “Strong Buy” rating with a price target of $80.56.
• Potential risks include XDEMVY adoption rates and high operating costs.

Investors should carefully weigh the potential rewards against the inherent risks before making investment decisions regarding Tarsus Pharmaceuticals.